LFSCF/m Emerald Life Sciences Innovation ETF
Seeks long-term capital appreciation.
By Emerald Mutual Fund Advisers Trust · Launched 2024
Annual Cost
0.54%
#2,850 of 5,854 · average
Fund Size
$122M
#2,803 of 5,854 · mid-size
Return (1Y)Goal
+87.5%
Track Record
1 year
#3,820 of 5,854 · seasoned
Performance
Total-return NAV · USDGrowth of $10,000
$18,804+88.0%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaCap
Multi cap
Strategy
Active selection
Sector
Health careFocus
Biotech & Genomics
What it actually holds
By weightConcentration
Top 10 holdings = 52.5% of fundmoderately concentrated
Cogent Biosciences Inc
9.0%
LivaNova PLC
7.4%
TransMedics Group Inc
5.3%
Mirum Pharmaceuticals Inc
4.8%
Travere Therapeutics Inc
4.6%
Spyre Therapeutics Inc
4.4%
United Therapeutics Corp
4.4%
Guardant Health Inc
4.3%
WaVe Life Sciences Ltd
4.2%
Savara Inc
4.0%
Asset allocation
Stocks
99.4%
Bonds
0.7%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
27.3%High
Year-on-year price swings
Max drawdown
-29.7%Moderate
Worst peak-to-trough loss
Sharpe (3Y)
Unavailable
Needs 3+ years of history
Sortino (3Y)
Not yet
Needs 3+ years of history
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Seeks long-term capital appreciation.
- Strategy
- Actively manages a portfolio primarily invested in equity securities of life science companies, focusing on innovative growth opportunities. Invests at least 80% of net assets in U.S. life science companies, including biotechnology, pharmaceuticals, and healthcare services.
- Inception date
- October 30, 2024
- Fund family
- Emerald Mutual Fund Advisers Trust
Similar funds
Same asset class, closest by strategy & exposureWhat's next?
You've looked at LFSC. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.
Data updated on 2026-08-03